Electrical Stimulation for Glymphatic Clearance

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods are inadequate in effectively enhancing glymphatic clearance of pathogenic proteins in the central nervous system, which are associated with neurodegenerative diseases such as Alzheimer's and Parkinson's, as they do not efficiently remove misfolded proteins like β-amyloid, α-synuclein, and tau, leading to detrimental effects.

Innovation Solution

Electrical stimulation is used to modulate glymphatic clearance by increasing interstitial fluid-cerebrospinal fluid exchange, reducing resistance to flow, and enhancing the permeability of aquaporin-4 water channels, thereby facilitating the removal of pathogenic proteins through mechanisms such as increasing CSF production, pulsatility of arterial vessels, and inducing slow wave oscillations during sleep.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If electrical stimulation is used to enhance glymphatic clearance, then protein removal efficiency is improved, but device complexity increases

Engineering Contradiction:
Improveprotein clearance efficiencyVSAvoidstimulation device complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent applies universality by using electrical stimulation to achieve multiple therapeutic effects simultaneously: enhancing glymphatic clearance of proteins, modulating neural activity, and treating various neurodegenerative conditions through a single device platform, thereby improving productivity without proportionally increasing complexity

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs parameter changes by adjusting electrical stimulation parameters (frequency, amplitude, pulse width) to optimize glymphatic clearance efficiency at different stages of proteinopathy, allowing the system to adapt to varying treatment needs while maintaining a relatively simple device architecture

Inventive Principle:
Principle #35Parameter changes

2Productivity

If continuous electrical stimulation is administered during sleep, then glymphatic clearance is enhanced, but energy consumption increases

Engineering Contradiction:
Improveglymphatic clearance enhancementVSAvoidenergy consumption
Core Design Contradiction:
ProductivityVSUse of energy by moving object

Solution Approach 1:

The patent applies periodic action by administering electrical stimulation in rhythmic patterns synchronized with sleep cycles and natural glymphatic activity, delivering stimulation only during periods when it is most effective for protein clearance, thereby reducing overall energy consumption while maintaining therapeutic productivity

Inventive Principle:
Principle #19Periodic action

Solution Approach 2:

The patent employs self-service by designing the stimulation protocol to leverage the body's own physiological rhythms and mechanisms, where the electrical stimulation works synergistically with natural glymphatic flow patterns rather than opposing them, reducing the energy required to achieve therapeutic effects

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The electrical stimulation method enhances glymphatic clearance by up to 10-20% during sleep, reducing the severity of proteinopathies and potentially minimizing the need for sleep, thereby mitigating cognitive decline and improving protein clearance efficiency.

Implementation Method 1

administering electrical stimulation to the mammal under conditions wherein the electrical stimulation is effective to enhance glymphatic clearance of one or more pathogenic proteins from the central nervous system of the mammal

Methodology Applied
Scientific EffectElectrical stimulation: Electrical Impedance Tomography

Implementation Method 2

The electrical stimulation to the mammal may be under conditions wherein the electrical stimulation is effective to increase CSF production

Methodology Applied
Scientific EffectElectrical stimulation: Electrical Impedance Tomography

Implementation Method 3

The electrical stimulation to the mammal may be under conditions wherein the electrical stimulation is effective to modulate pulsatility of penetrating arterial vessels

Methodology Applied
Scientific EffectElectrical stimulation: Electrical Impedance Tomography

Implementation Method 4

The electrical stimulation to the mammal may be under conditions wherein the electrical stimulation is effective to increase aquaporin-4 (AQP4) water channel permeability

Methodology Applied
Scientific EffectElectrical stimulation: Electrical Impedance Tomography

Implementation Method 5

The electrical stimulation to the mammal may be under conditions wherein the electrical stimulation is effective to decrease the resistance of CSF penetration in the ISF space

Methodology Applied
Scientific EffectElectrical stimulation: Electrical Impedance Tomography

Implementation Method 6

The electrical stimulation to the mammal may be under conditions wherein the electrical stimulation is effective to induce slow wave oscillations in specific brain areas

Methodology Applied
Scientific EffectElectrical stimulation: Electrical Impedance Tomography

Implementation Method 7

The electrical stimulation to the mammal may be under conditions wherein the electrical stimulation is effective to draw charged proteins toward venous return

Methodology Applied
Scientific EffectElectrical stimulation: Electrophoresis

Data Source

PatentUS20240307681A1Neuromodulation to Modulate Glymphatic Clearance
Publication Date: 2024.09.19 WISCONSIN ALUMNI RES FOUND
  • US20240307681A1 patent drawing
  • US20240307681A1 patent drawing

AI summary

The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.